Valsassina Maria V
Instituto Português de Oncologia de Francisco Gentil, Lisboa.
Acta Med Port. 2002 Nov-Dec;15(6):461-4.
The inflammatory breast cancer corresponds to 1-6% of breast tumors. It is an aggressive clinical entity being characterised by the incidence of local relapse and distant metastases superior to the other breast malign entities. Changes in its therapy have been observed: progressive innovating therapeutic strategies have been adopted, tendentiously multimodal ones, trying to alter the course of this pathology of such a unfavourable prognosis. Here we show a revision of the most significant facts in the evolution of the inflammatory breast carcinoma diagnosis and treatment, both as to the present development and future perspectives. Aspects of clinical diagnosis are emphasized as well as their corroboration with complementary diagnosis technics and their evolution before different approaching therapies.
炎性乳腺癌占乳腺肿瘤的1%-6%。它是一种侵袭性的临床实体，其局部复发和远处转移的发生率高于其他乳腺恶性实体。人们观察到其治疗方法有所变化：已采用了逐步创新的治疗策略，倾向于多模式治疗策略，试图改变这种预后不良的病理过程。在此，我们对炎性乳腺癌诊断和治疗进展中最重要的事实进行综述，包括当前的发展情况和未来展望。文中强调了临床诊断方面，以及它们与辅助诊断技术的相互印证，还有在不同治疗方法之前的演变情况。
